In a phase II clinical trial, 21 treatment-naïve metastatic NSCLC patients with tumor PD-L1 ≥50% were treated with pembrolizumab and delayed itacitinib (a JAK1 inhibitor) (151). The gene discussed is CD274; the disease is neoplasm.